GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » WACC %

Adhera Therapeutics (Adhera Therapeutics) WACC %

:33.41% (As of Today)
View and export this data going back to 1993. Start your Free Trial

As of today (2024-04-18), Adhera Therapeutics's weighted average cost of capital is 33.41%%. Adhera Therapeutics's ROIC % is -8.16% (calculated using TTM income statement data). Adhera Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Adhera Therapeutics WACC % Historical Data

The historical data trend for Adhera Therapeutics's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
WACC %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.64 20.56 27.98 17.98 31.17

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
WACC % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.88 31.17 35.76 40.73 32.94

Competitive Comparison

For the Biotechnology subindustry, Adhera Therapeutics's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics WACC % Distribution

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's WACC % distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's WACC % falls into.



Adhera Therapeutics WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Adhera Therapeutics's market capitalization (E) is $0.043 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Sep. 2023, Adhera Therapeutics's latest one-year quarterly average Book Value of Debt (D) is $9.5246 Mil.
a) weight of equity = E / (E + D) = 0.043 / (0.043 + 9.5246) = 0.0045
b) weight of debt = D / (E + D) = 9.5246 / (0.043 + 9.5246) = 0.9955

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.522%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Adhera Therapeutics's beta is 0.09.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.522% + 0.09 * 6% = 5.062%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Sep. 2023, Adhera Therapeutics's interest expense (positive number) was $3.194 Mil. Its total Book Value of Debt (D) is $9.5246 Mil.
Cost of Debt = 3.194 / 9.5246 = 33.5342%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -4.133 = 0%.

Adhera Therapeutics's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.0045*5.062%+0.9955*33.5342%*(1 - 0%)
=33.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adhera Therapeutics  (OTCPK:ATRX) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Adhera Therapeutics's weighted average cost of capital is 33.41%%. Adhera Therapeutics's ROIC % is -8.16% (calculated using TTM income statement data). Adhera Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Adhera Therapeutics (Adhera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.
Executives
Zahed Subhan director 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness director 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: Chief Executive Officer 549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley officer: SVP Finance & Accounting 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan director 812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague officer: Chief Financial Officer C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell director 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato officer: CEO 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris director 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein officer: Chief Legal Officer C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah officer: Chief Financial Officer 10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson officer: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif officer: Chief Operating Officer 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679